Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
1 April 2022, 07:00 CET

LIÈGE, Belgium , April 01, 2022 (GLOBE NEWSWIRE) --  Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) (the "Company” or "Hyloris”), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces today that it successfully raised an amount of EUR 15.0 million in gross proceeds, from new and existing, local and international investors, through an equity offering by means of a private placement via an accelerated bookbuild offering of 967,742 new shares (being approximately 3.7% of the Company's outstanding shares (pre-transaction)) at an issue price of EUR 15.50 per share (the "Offering"), representing a discount of 1.6% to the 30-day VWAP.

Stijn Van Rompay, Chief Executive Officer and co-founder of Hyloris, commented: "We are delighted to have completed this transaction at a tight discount in challenging market conditions, and are particularly pleased with the continued strong support from our existing investors as well as welcoming new investors. This transaction further strengthens our financial position as we continue to drive forward our pipeline of repurposed drugs in areas of high unmet medical needs and endeavour to grow shareholder value. We are excited for the year ahead where we plan to add four new innovative product candidates to our pipeline.”

Hyloris will use the net proceeds of the Offering primarily to fund the development of new products and accelerate in-house R&D activities.

Joh. Berenberg, Gossler & Co. KG ("Berenberg”), KBC Securities NV ("KBC Securities") and Stifel Nicolaus Europe Limited ("Stifel”) are acting as Joint Global Coordinators and Joint Bookrunners in the Offering (jointly, the "Underwriters").

The new shares have been placed with certain qualified and/or institutional investors as provided in the applicable laws and regulations and certain other investors who acquired new shares for a total consideration of at least €100,000 per investor.

The payment and delivery of the new shares is expected to take place on 5 April 2022, and an application will be made to admit the new shares to trading on the regulated market of Euronext Brussels at the same time. The new shares to be issued will have the same rights and benefits as, and rank pari passu in all respects, including as to entitlement to dividends and distributions, with, the existing and outstanding shares of Hyloris at the moment of their issuance.

As a result of the issuance of new shares, the Company's outstanding shares will increase from 25,832,632 to 26,800,374 shares.

In relation to the Offering, the Company has agreed with the Underwriters to a customary 180-day standstill period on future share issuances, waivable by the Underwriters and subject to customary exceptions.

For more information, contact:

Hyloris Pharmaceuticals, Investors and Media

investorrelations@hyloris.com

About Hyloris Pharmaceuticals

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 14 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Outside of its core strategic focus, the Company also has 4 high barrier generic products in development and registration phase. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

Important information

These written materials, and any copy thereof, may not be directly or indirectly distributed in or to persons resident in the United States, Canada, Japan, Australia, South Africa or any other jurisdiction where such distribution could constitute a breach of the applicable laws of such jurisdiction.

These written materials are for information purposes only and are not intended to constitute, and should not be construed as, an offer to sell or subscribe for, or the announcement of a forthcoming offer to sell or subscribe for, or a solicitation of any offer to buy or subscribe for, or the announcement of a forthcoming solicitation of any offer to buy or subscribe for, existing or new shares of the Company in the EEA (except in the context of a private placement with Qualified Investors, as defined below), the United States, Canada, Switzerland (except in the context of a private placement with Professional Clients, as defined below), Japan, Australia, the United Kingdom (except in the context of a private placement with UK Relevant Persons, as defined below) or South Africa. No offer to sell or subscribe for shares, or announcement of a forthcoming offer to sell or subscribe for shares, will be made in the EEA (except in the context of a private placement with Qualified Investors, as defined below), the United States, Canada, Switzerland (except in the context of a private placement with Professional Clients, as defined below), Japan, Australia, the United Kingdom (except in the context of a private placement with UK Relevant Persons, as defined below) or South Africa, or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction, and the distribution of this communication in such jurisdictions may be similarly restricted. Persons into whose possession this communication comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the security laws of any such jurisdiction.

This announcement contains statements that are "forward-looking statements” or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the Company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

This communication does not constitute or form part of an offer of securities in the United States, or a solicitation to purchase securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act”), or under the securities law of any state or jurisdiction in the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly within the United States except pursuant to an applicable exemption from the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or jurisdiction of the United States. The issuer of the securities has not registered, and does not intend to register, any portion of the transaction in the United States. There will be no public offer of securities in the United States.

In relation to each Member State of the European Economic Area (each a "Relevant Member State”) an offer of securities to which this communication relates is only addressed to and is only directed at qualified investors in that Relevant Member State within the meaning of Regulation ((EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, and any implementing measure in each Relevant Member State of the EEA (the "Prospectus Regulation”)) (all such persons together referred to as the "Qualified Investors”).

In relation to the United Kingdom, this announcement is only addressed to, and is only directed at, "qualified investors” within the meaning of Article 2 of the Prospectus Regulation amended and transposed into the laws of the United Kingdom law by virtue of the European Union (Withdrawal) Act of 2018 and the European Union (Withdrawal Agreement) Act 2020 (the "UK Prospectus Regulation”) (all such persons together referred to as the "UK Relevant Persons”).

In relation to Switzerland, this announcement is only addressed to, and is only directed at, investors that qualify as "professional clients” within the meaning of the Swiss Federal Act on Financial Services ("Finanzdienstleistungsgesetz”) of 15 June 2018, as amended ("FinSA”) (such persons referred to as "Professional Clients”).